NFL Biosciences General Meeting Results

On May 21, 2025, NFL Biosciences held its combined general meeting in Montpellier. Under the chairmanship of Bruno Lafont, all resolutions proposed by the Board of Directors, with the exception of the 14th resolution on company savings plans, were adopted. The meeting was attended by 27 shareholders, representing 37.13% of the voting shares and 44.68% of the voting rights.

NFL Biosciences, listed on Euronext Growth Paris, focuses on the development of botanical drugs to combat addiction. The detailed report of the meeting is available on their website. This meeting marks a milestone in the company's strategic advancement in the biopharmaceutical market.